ALPS Advisors’s Forte Biosciences FBRX Stock Holding History

ALPS Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$264K	Sell	10,200 -89	-0.9%	-$2.56K	﹤0.01%	980
2025 Q4	$281K	Buy	+10,289	New	+$180K	﹤0.01%	944
2021 Q4	–	Sell	-682	Closed	-$50K	–	922
2021 Q3	$50K	Sell	682 -30	-4%	-$16.6K	﹤0.01%	906
2021 Q2	$598K	Buy	+712	New	+$642K	0.01%	496
2019 Q2	–	Sell	-148	Closed	-$603K	–	886
2019 Q1	$603K	Buy	148 +25	+20%	+$96.6K	﹤0.01%	454
2018 Q4	$379K	Buy	123 +29	+31%	+$125K	﹤0.01%	648
2018 Q3	$550K	Buy	94 +17	+22%	+$64.7K	﹤0.01%	542
2018 Q2	$270K	Buy	77 +6	+8%	+$22K	﹤0.01%	885
2018 Q1	$315K	Buy	71 +12	+20%	+$55.6K	﹤0.01%	812
2017 Q4	$225K	Buy	59 +7	+13%	+$27.9K	﹤0.01%	798
2017 Q3	$243K	Buy	52 +4	+8%	+$17.8K	﹤0.01%	743
2017 Q2	$215K	Buy	+48	New	+$270K	﹤0.01%	747

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

ALPS Advisors's FBRX Position: Q1 2026 in Review

ALPS Advisors reduced its Forte Biosciences (FBRX) stake by 0.87% in Q1 2026, selling an estimated $2.56K and leaving 10,200 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #980.

ALPS Advisors first reported a position in FBRX in Q2 2017 and has held it in 12 quarters since. The position peaked at $603K in Q1 2019. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

ALPS Advisors held 10,200 shares of Forte Biosciences worth $264K as of Q1 2026.
ALPS Advisors sold 89 Forte Biosciences shares in Q1 2026, an estimated $2.56K.
Forte Biosciences made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #980 holding.
ALPS Advisors first reported a position in Forte Biosciences in Q2 2017 and has held it in 12 quarters since.
ALPS Advisors's Forte Biosciences position peaked at $603K in Q1 2019.
68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.